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Introduction
Systemic lupus erythematosus (SLE [MIM 152700]) is a
chronic autoimmune disease that is classically character-
ized by inflammation, dysregulated type 1 interferon
responses, and autoantibodies directed to the nuclear
compartment. Women of childbearing age are preferen-
tially affected at a rate nine times that of men, and those
of African American and Asian ancestries are affected
more frequently and manifest more severe disease than
those of European ancestry.1 Although the etiology of SLE
is largely unknown, its pathogenesis most likely involves
a complex interplay between environmental (e.g., UV light,
Epstein-Barr virus infection, etc.) and genetic (e.g., MHC,
IRF5 [MIM 607218], etc.) components.2 A sibling risk ratio
(ls) of approximately 30 in SLE illustrates a strong genetic
component,3 and the fact that observational studies have
identified many families with multiple cases of SLE and
other autoimmune conditions suggests the potential for
shared genetic predisposition.4–6
Candidate-gene studies and, more recently, genome-
wide association (GWA) scans have been highly successful
in identifyingmultiple susceptibility loci.2,7 The histocom-
patibility leukocyte antigen (HLA) region has been known
to contribute to the risk of SLE and other related autoim-
mune diseases since the 1970s.8–11 In the early 2000s,
gene expression studies determined that, compared to
healthy controls, individuals with SLE overexpress genes
in the interferon pathway.12–14 Association between SLE
and variants in the region of IRF5 was first reported in
2005 and has since been replicated in most GWA scans
of SLE.15–19 In 2008, four GWA scans of SLE cases of
European descent were published, and the first GWA
scan of Asian descent was published in 2009.16,17,19–21
Collectively, these studies have identified and confirmed
~35 loci that contribute to the pathogenesis of SLE. These
data highlight the importance of several pathways,
including those involving lymphocyte activation and
function, immune-complex clearance, innate immune
response, and adaptive immune responses.2 However,
a substantial portion of the heritable risk has yet to be iden-
tified.17,22 The lack of causal variants, rare variants, and/or
other loci yet to be discovered might account for the
missing heritability.
In an effort to identify regions contributing to SLE risk,
we sought to replicate suggestive association signals in
our previously published European American SLE GWA
scan.19 We evaluated 1,580 single-nucleotide polymor-
phisms (SNPs) in an independent population of 7,998
SLE cases and 7,492 controls of European, African Amer-
ican, Asian, Hispanic, Gullah, and Amerindian ancestry
(Tables S1–S3, available online). Three loci, interferon
regulatory factor 8 (IRF8 [MIM 601565]), transmembrane
protein 39A (TMEM39A), and the region between IKAROS
family of zinc finger 3 (AIOLOS; IKZF3 [MIM 606221]) and
zona pellucida binding protein 2 (ZPBP2 [MIM 608449])
exceeded the genome-wide significance threshold (p <The Am5 3 108). Through fine mapping, resequencing, and
imputation of the IRF8 region, we identified three inde-
pendent effects required for risk. Moreover, we replicated
11 other loci, several of which had been previously re-
ported in related conditions.Subjects and Methods
GWA Scan
Genotyping, quality control, procedures for data analysis, and
summary statistics for the GWA scan were described previously
in Graham et al., 2008.19
Study Design
The genotype data used in this study were generated as a part of
a joint effort of more than 40 investigators from around the world.
These investigators contributed samples, funding, and hypotheses
on a combined array containing ~35,000 SNPs (Figure S1). The
Oklahoma Medical Research Foundation (OMRF) served as the
coordinating center, ran the arrays, and sent the data to a central
facility for quality control at Wake Forest Medical Center. These
data were then distributed back to the investigators, who re-
quested the SNPs for final analysis and publication.23–28
Subjects
Themultiracial replication study consisted of 17,003 total samples
(8,922 SLE cases and 8,077 controls) and included individuals
of self-reported African American, Asian, European, Gullah,
Hispanic, and Amerindian ancestry (Table S1). A total of 374
samples were common between the GWA scan and the replication
study so that genotypes generated by the two platforms could
be confirmed and so that genotypes of SNPs not present on the
Affymetrix 5.0 array could be obtained. These data were only
used as observed data for the imputation analysis of specific
genomic regions, as described below; to maintain independence
between the GWA scan and replication samples, we did not
include the data generated on these shared samples in the replica-
tion or fine-mapping analyses. The OMRF gathered the samples
from consenting subjects (according to the guidelines of the ethics
committees at the respective institutions where the samples were
collected) and prepared them for genotyping. All cases used in this
study fulfilled at least 4 of the 11 American College of Rheuma-
tology criteria for SLE, whereas the healthy, population-based
controls did not have any family history of SLE or any other auto-
immune disease.29
Genotyping and Sample Quality Control
A total of 1,580 SNPs that attained p < 0.05 in the previously pub-
lished GWA scan were selected for replication. In addition, 287
SNPs (chosen to capture all variation with aminimum r2 threshold
of 0.8 via the TAGGER algorithm in HAPLOVIEW30) within the
IRF8 region and 347 ancestral-informative markers (AIMs) span-
ning the genome were genotyped. Genotyping of SNPs was per-
formed at OMRF with Infinium chemistry on an Illumina iSelect
custom array according to the manufacturer’s protocol. The
following quality-control procedures were implemented prior to
the analysis (Table S2): there were well-defined clusters within the
scatter plots, the SNP call rate was >90% across all samples geno-
typed, the minor allele frequency was >1%, the sample call rate
was >90%, p > 0.05 for differential missingness between cases
and controls, the total proportion missing was <5%, and theerican Journal of Human Genetics 90, 648–660, April 6, 2012 649
Hardy-Weinberg proportions were p > 0.01 in controls and p >
0.0001 in cases.
Samples exhibiting excess heterozygosity (>5 standard devia-
tions [SDs] from the mean) or a <90% call rate were excluded
from the analysis. The remaining individuals were examined for
excessive allele sharing as estimated by identity-by-descent
(IBD). In sample pairs with excess relatedness (IBD > 0.4), one
individual was removed from the analysis on the basis of the
following criteria: (1) remove the sample with the lower call rate,
(2) remove the control and retain the case, (3) remove the male
sample before the female sample, (4) remove the younger control
before the older control, and (5) in a situation with two cases, re-
move the case with fewer phenotype data available. Discrepancies
between self-reported and genetically determined gender were
evaluated. Males were required to be heterozygous at rs2557523
(given that the G allele for this SNP is only observed on the
Y chromosome and the A allele appears only on the X chromo-
some) and to have%10% chromosome X heterozygosity. Females
were required to be homozygous for the A allele at rs2557523 and
to have >10% chromosome X heterozygosity.Ascertainment of Population Stratification
Genetic outliers from each ethnic and/or racial group were
removed from further analysis as determined by principal-compo-
nent analysis and admixture estimates (Figure S6).31,32 Using the
163 AIMs that passed quality control in both EIGENSTRAT31 and
ADMIXMAP33,34 to distinguish the four continental ancestral pop-
ulations—Africans, Europeans, Amerindians, and East Asians—
allowed identification of the substructure within the sample
set (Figure S6A).35,36 We utilized principal components from
EIGENSTRAT outputs to identify outliers >4 SDs from the mean
of each of the first three principal components (PC) for the indi-
vidual population clusters. After quality control, a total of 1,139
samples were excluded (Figure S6B and Table S3). Overall, 2,586
subjects were included in the GWA scan, and 15,490 subjects
were included in the replication study, resulting in a total of
18,076 subjects.Statistical Analysis
Testing for SNP-SLE association in the replication studywas carried
out through the computation of logistic regression as imple-
mented in PLINK v.1.07.37 The calculation of the additive genetic
model included adjustments for the first three PCs and gender.
Models were also adjusted for ancestry with estimates provided
by ADMIXMAP and resulted in no observable difference in associ-
ation as comparedwith PC adjustment.We conducted conditional
likelihood-ratio tests by using the extended WHAP functionality
in PLINK v.1.07. The genome-wide p value threshold for all data
replicating GWA-scan results was p< 53 108 after meta-analysis.
For the finemapping and imputation of IRF8, we utilized a Bonfer-
roni-corrected p value threshold of p< 1.093 104 on the basis of
the maximum number of tests across all populations (460 inde-
pendent variants with r2 < 0.8). Using METAL,38 we performed
meta-analyses of the SNPs observed in both the GWA scan and
the multiracial replication study with a weighted Z score. Each
racial group was weighted by the square root of its sample size
so that sample-size differences could be controlled for between
studies. We combined all data generated unless the variant failed
quality control in a given racial group.
To test for meta-analysis heterogeneity, we utilized both Co-
chran’s Q test and the I2 index. Cochran’s Q test is a classical650 The American Journal of Human Genetics 90, 648–660, April 6, 2method that calculates the weighted sum of the squared devia-
tions between individual study effects and the overall effect across
studies.39 It follows a chi-square distribution with k-1 degrees of
freedom (k is the number of studies). A value of p < 0.05 was
considered significant evidence of heterogeneity. The I2 index
measures the degree or percentage of inconsistency—due to
heterogeneity rather than random chance—across studies.40 The
I2 index ranges from 0% to 100% and can equal 0%–25% (low
heterogeneity), 26% –50% (moderate heterogeneity), 51%–75%
(high heterogeneity), or 76%–100% (very high heterogeneity).
Linkage disequilibrium (LD) and probable haplotypes were
determined with HAPLOVIEW v.4.2.30 We calculated haplotype
blocks for those haplotypes present at >3% frequency by using
the solid-spine of LD algorithms with minimum r2 values of
0.8.30Resequencing
We resequenced the IRF8 region (chromosome 16: 84,488,150–
84,539,352 bp) in 206 (92 SLE cases and 114 healthy controls)
European and 46 (25 SLE cases and 21 healthy controls) African
American subjects. For each sample, 3–5 mg of whole genomic
DNA were sheared and prepared for sequencing with an Illumina
Paired-End Genomic DNA Sample Prep Kit. Targeted regions of
interest from each sample were then enriched with a SureSelect
Target Enrichment System utilizing a custom-designed bait pool
(Agilent Technologies). Resequencing was undertaken with an
Illumina GAIIx platform according to standard procedures. Post-
sequence data were processed with Illumina’s Pipeline software
v.1.7. All samples were sequenced to minimum average fold
coverage of 253.Variant Detection and Quality Control
Unique sequences corresponding to an individual nucleotide
molecule were aligned to the human genome reference (hg18)
with the Burrows-Wheeler Aligner (BWA)41 alignment tool. Reads
were locally realigned around known and suspected insertion and
deletion sites with the Genome Analysis Toolkit (GATK) analysis
suite so that the best possible read alignment could be gener-
ated.42 Recalculation of the correct quality score for each base
within the alignment was then performed empirically with the
GATK suite. This process served to correct overestimated high-
quality scores initially reported by the sequencer itself.
After local realignment around deletion-insertion polymor-
phism (DIP) sites and base quality-score recalibration, SNP and
DIP genotypes were generated for each sample individually as
well as for the samples as a whole. Finally, SNP and DIP genotypes
were hard-filtered against a set of criteria designed to remove any
remaining low-quality calls. For a variant to be included in the call
list, we required a Phred quality score>30, a quality-by-depth ratio
of >5.0, a strand bias score of <0.10, and a homopolymer
run of <5 bases. The variant phase was determined with the
program BEAGLE.43 Variants meeting call parameters were output
to files compatible with PLINK and other genotyping tools via the
VCFtools analysis suite.
To assess the accuracy of sequence-based SNP calling, we cross-
referenced the sequenced and genotyped allele calls. We observed
~99% concordance between genotypes and sequence-based var-
iant detection, suggesting high-quality sequence data. We manu-
ally inspected the samples withR5% of variants differing between
sequencing and genotyping to determine where sequence quality
was poor. As an additional quality-control measure, we confirmed012
each variant identified by our automated workflow by manual
inspection of the assembled contig by using the Integrative
Genomics Viewer (IGV) program.44Imputation
To increase the informativeness of the IRF8 region, we conducted
imputation in subjects of European, African American, and Asian
ancestry over a 100 kb interval spanning the IRF8 locus. Imputa-
tion of the replication data across chromosome 16 (84.45–84.46
Mb) was performed with IMPUTE2 and the reference panels
provided in Table S7.45–47 Imputed genotypes were required to
meet or exceed a probability threshold of 0.8, an information
measure of >0.4, and the same quality-control-criteria thresholds
described above for inclusion in the analyses.Results
Two SNPs, rs11648084 and rs11644034, telomeric to IRF8
at 16q24.1 were suggestive of association with SLE in
our published GWA scan (p ¼ 5.99 3 104 and 2.29 3
103, respectively; odds ratio [OR] ¼ 0.76 and 0.66,
respectively; Table 1). Both rs11648084 and rs11644034
were replicated in the current, independent population
of SLE cases and controls of European ancestry and
exceeded the genome-wide threshold (pmeta-Euro ¼ 2.34 3
109 and pmeta-Euro ¼ 2.08 3 1010, respectively; Table 1).
However, neither SNP was significantly associated with
SLE in any other population studied, perhaps as a result
of the reduced sample size, clinical and/or genetic
heterogeneity, decreased minor allele frequency, and/or
reduced correlation with the causal variants (Table 1 and
Table S4).
To better refine the association signal, 287 additional
SNPs covering ~100 kb encompassing the IRF8 coding
region were genotyped (see Subjects and Methods; Figures
1A and 1D, Table 2, and Table S4). The most significant
association in the European population was with
rs9936079 (p ¼ 3.96 3 109, OR ¼ 0.77; Figures 1A and
1D and Table 2), located ~11 kb telomeric to IRF8 and
found to be in strong LD with rs11644034 (r2 ¼ 0.92;
Figures 2B and 2C). The Asian population also exhibited
association with rs9936079 (p ¼ 2.95 3 103, OR ¼
0.73); however, rs9936079 failed to pass quality-control
measures (see Subjects and Methods; differential missing-
ness p ¼ 107) in individuals of African ancestry and
was not associated with disease in patients of Hispanic
or Amerindian ancestry. Meta-analysis yielded pmeta-all ¼
9.28 3 1011 (Table 2 and Table S4).
We observed a modest association in the African Ameri-
cans at rs2934498 (p¼ 3.923 104, OR¼ 0.83), which was
also significant in those individuals of European ancestry
(p ¼ 5.96 3 106, OR ¼ 1.19) but not in those of Asian
ancestry (Figure 1B,D, Table 2, and Table S4). The strongest
Asian association was observed in a region (rs11117427,
p ¼ 1.99 3 105, OR ¼ 0.64) ~34 kb telomeric to IRF8
(Figures 1C and 1D, Table 2, and Table S4). Association
was also observed with rs11117427 (p ¼ 3.46 3 104,The AmOR ¼ 0.84) in the Europeans (Figures 1A and 1D and Table
2). Interestingly, this SNP is only ~2 kb away from
rs12444486, which has been reported by Gateva et al.22
as being suggestive of association with SLE in Europeans
(Figure 1D and Table S4).
We resequenced the IRF8 region in 206 subjects of
European ancestry and in 46 subjects of African American
ancestry to identify variants not previously evaluated
within the IRF8 region and to assess their association
with SLE (see Subjects and Methods). Thirty-eight and
85 variants not present in dbSNP 130 were identified in
European and African American individuals, respectively.
After imputing these data into our larger European and
African American datasets (see Subjects and Methods),
the most significantly associated region within the
European population was ~19 kb telomeric to IRF8
(rs4843869, p ¼ 7.61 3 1010, OR ¼ 0.76; Table 2 and
Figures 1A and 1D). Ultimately, three strongly correlated
(r2 > 0.90) SNPs emerged as the most significantly associ-
ated with SLE in the Europeans: rs11644034 (identified
via GWA scan), rs9936079 (identified by fine mapping),
and rs4843869 (imputed on the basis of resequencing).
Interestingly, our targeted resequencing revealed a DIP
(rs11347703, p ¼ 1.113 108, OR ¼ 0.78) that was located
less than 100 bp from a genotyped SNP, rs8052690
(p ¼ 5.69 3 108, OR ¼ 0.79, Table 2). This DIP,
which has high biological plausibility, was in strong LD
with the peak European SNP (rs4843869) and rs8052690
(r2/D’ > 0.9; Figures 2B and 2C). Of note, some of
the African Americans resequenced in this study did
harbor the DIP (rs11347703) identified in the Europeans.
However, neither rs11347703 nor any SNP correlated
with it was found to be significantly associated with
SLE in African Americans, which could be due to the
decrease in power and/or a decrease in the minor allele
frequency.
The peak association in African Americans after imputa-
tion was at rs450443 (p ¼ 1.41 3 104, OR ¼ 0.82; Table 2
and Figures 1B and 1D) and was in strong LD (r2 ¼ 0.88)
with rs2934498. Patients of European but not Asian
ancestry showed association with rs450443 (p ¼ 9.73 3
106, OR ¼ 1.18; Table 2 and Figures 1A, 1C, and 1D).
We conducted imputation in the Asian population by
using 1,000 Genomes phased haplotypes;48 however,
rs11117427 remained the peak signal (Table 2 and Figures
1C and 1D).
To assess the independence of variants in the European
population, we used logistic regression models that
adjusted for the best tagging SNP at each signal. When
we adjusted for rs4843869 in Europeans, the association
persisted at rs450443, and variants correlated to it.
However, adjusting for rs4843869 negated the association
with rs11117427 and its correlated variants (Figures 2B,
2C, and 3, Table S5, and Figure S2A). Adjusting for either
rs450443 or rs11117427 was only able to negate the asso-
ciations of the polymorphisms that were correlated with
each of these SNPs (Figures 2B, 2C, and 3, Table S5, anderican Journal of Human Genetics 90, 648–660, April 6, 2012 651
Table 1. SLE Risk Loci Surpassing the Genome-wide Significance Thresholda
Chr SNP Locus Allelesb
European (3,562 Cases/3,491 Controls)
African American
(1,527 Cases/1,811
Controls)
Asian
(1,265 Cases/1,260
Controls) Meta
Test of
Heterogeneity
pGWA scan
c
ORGWA scan
(95% Cl) pREP
ORREP
(95% Cl) pMETA-Euro p OR (95% Cl) p OR (95% Cl) pMETA-ALL
d pQ
e I2
3 rs1132200 TMEM39A G/A 1.65 3 103 0.72
(0.59–0.88)
2.37 3 104 0.83
(0.76–0.92)
1.81 3 106 6.92 3 102 0.75
(0.56–1.02)
1.66 3 103 0.73
(0.59–0.89)
8.62 3 109 0.450 0.0%
16 rs11644034 IRF8 G/A 2.29 3 103 0.66
(0.54–0.79)
2.36 3 108 0.78
(0.71–0.85)
2.08 3 1010 5.10 3 101 0.95
(0.81–1.11)
2.63 3 102 0.79
(0.65–0.97)
2.72 3 109 0.016 61.5%
16 rs11648084 IRF8 G/A 5.99 3 104 0.76
(0.65–0.89)
9.35 3 107 0.83
(0.77–0.89)
2.34 3 109 6.33 3 102 0.90
(0.81–1.01)
7.52 3 101 1.02
(0.91–1.14)
7.00 3 107 0.001 74.0%
17 rs9913957 IKZF3 A/G 7.87 3 103 1.75
(1.27–2.41)
5.14 3 104 1.38
(1.15–1.66)
1.38 3 105 1.07 3 102 1.22
(1.05–1.41)
  1.39 3 108 0.105 45.1%
17 rs8076347 IKZF3 C/A 3.07 3 103 1.93
(1.41–2.62)
3.04 3 103 1.32
(1.10–1.58)
4.75 3 105 2.19 3 103 1.20
(1.07–1.34)
  3.01 3 108 0.047 55.4%
17 rs8079075 IKZF3 A/G 1.47 3 103 1.90
(1.39–2.59)
5.08 3 104 1.39
(1.16–1.68)
3.81 3 106 2.62 3 103 1.26
(1.08–1.46)
  4.83 3 109 0.201 31.3%
17 rs1453560 ZPBP2 A/C 7.81 3 104 1.92
(1.41–2.61)
6.42 3 104 1.37
(1.14–1.64)
3.21 3 106 4.86 3 104 1.23
(1.09–1.37)
  3.48 3 1010 0.097 46.4%
The following abbreviations are used: Chr, chromosome; OR, odds ratio; GWA, genome-wide association; REP, replication; and CI, confidence interval.
aTable S7 contains results for all populations evaluated within this study.
bMajor/minor alleles.
cResult of GWA scan was previously reported in Graham et al.1
dData were combined for all racial groups genotyped within our study that passed quality control.
eCochran’s Q test statistic.
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Figure 1. Variants in the Region of IRF8
Tested for Association with SLE
The association between IRF8 and SLE in
European (A), African American (B), and
Asian (C) ancestral populations is given
with observed (blue diamonds) and
imputed (red circles) variants. The dotted
line represents the Bonferroni-corrected
threshold (p ¼ 1.09 3 104) for the fine-
mapping study. The solid black line repre-
sents the recombination rate. The variants
labeled with blue text represent the most
significant observed SNPs, whereas the
variants labeled in red represent the
most significant SNPs after imputation.
In the Asians, rs11117427 was both the
most significant observed and imputed
variant.
(D) Shown is an expanded view of
the most statistically significant region
in Europeans (circles), African Americans
(triangles), and Asians (squares) for
selected variants tagged by rs8046526
(purple), rs450443 (turquoise), rs4843869
(yellow-orange), and rs11117427 (green).
The following abbreviation is used:
Recomb., recombination.Figures S2B and S2C). A SNP (rs8046526) in the sixth
intron of IRF8 was also associated with SLE risk in
Europeans (p ¼ 3.96 3 106, OR ¼ 0.80) and remained
significant after adjusting for the other SNPs (Table 2,
Figures 1A, 1D, 2B, 2C, and 3, Table S5, and Figure S2D).The American Journal of HumanAdjusting for rs8046526 in the Euro-
peans only negated associations for
itself and its correlated variants.
However, adjusting the logistic regres-
sion model for rs8046526, rs450443,
and rs4843869 negated all associa-
tions present in the European popula-
tion (Figures 2B, 2C, and 3, Table S5,
and Figure S2E), demonstrating the
importance of these three IRF8 vari-
ants for SLE risk.
Haplotype analysis identified a
single risk haplotype (H2) (p¼ 6.423
108) with a frequency of 18.4% in
the European individuals (Figure 2).
Two significant protective haplo-
types, H6 and H7, were also identified
(Figure 2). The risk-associated alleles
within the region bounded by SNPs
rs11117426–rs34912238 (the peak
Asian effect) were also present in the
most significant protective haplo-
type, H7, suggesting that this region
might not impact disease risk in
Europeans (Figure 2). The only differ-
ences between H3 and H6 as well as
between H4 and H7 are rs8046526and rs8058904 in the minor form, suggesting that these
SNPs are important in conferring protection from disease
(Figure 2). The only differences between H2 and H5 (which
are not statistically significant) are the major alleles (for
SNPs rs8046526 and rs8058904) residing on the H2Genetics 90, 648–660, April 6, 2012 653
Table 2. IRF8 Variants Associated with SLEa
SNP
Genotyped
or Imputed Position (bp)
European
pAfrican-American pAsianAlleles
b MAFc p OR (95% Cl)
rs8046526 I 84,509,136 C/T 0.14/0.16 3.96 3 106 0.80 (0.73–0.88)  
rs8058904 G 84,509,183 A/G 0.14/0.16 5.14 3 106 0.80 (0.73–0.88) 1.96 3 101 
rs9936079 G 84,525,095 G/A 0.17/0.22 3.96 3 109 0.77 (0.70–0.84)  2.95 3 103
rs385344 I 84,525,105 C/G 0.30/0.27 1.37 3 105 1.18 (1.10–1.27)  2.43 3 101
rs34337659 I 84,525,158 T/C 0.31/0.27 1.55 3 105 1.18 (1.10–1.27) 3.97 3 104 1.14 3 101
rs66509440 I 84,525,182 C/T 0.28/0.25 6.36 3 106 1.20 (1.11–1.30) 3.97 3 104 
rs66804793 I 84,525,190 G/A 0.28/0.25 6.16 3 106 1.20 (1.11–1.30) 3.84 3 104 
rs74032085 I 84,525,245 T/C 0.28/0.24 2.25 3 106 1.22 (1.12-1.32) 4.72 3 104 
rs16940044 I 84,525,266 A/G 0.27/0.24 2.16 3 106 1.22 (1.12–1.32) 4.73 3 104 
rs2934497 I 84,525,379 C/T 0.27/0.23 2.62 3 107 1.24 (1.14–1.35) 5.12 3 104 1.95 3 101
rs2970091 I 84,525,387 G/A 0.28/0.24 2.96 3 107 1.24 (1.14–1.34) 5.31 3 104 1.93 3 101
rs2934498 G 84,525,783 A/G 0.31/0.27 5.96 3 106 1.19 (1.11–1.29) 3.92 3 104 2.09 3 101
rs439885 G 84,526,175 G/A 0.31/0.27 1.16 3 105 1.19 (1.10–1.28) 5.59 3 104 1.98 3 101
rs450443 I 84,526,392 T/G 0.30/0.27 9.73 3 106 1.18 (1.10–1.28) 1.41 3 104 2.04 3 101
rs396987 I 84,526,435 A/G 0.30/0.27 8.89 3 106 1.19 (1.10–1.28) 5.44 3 104 2.04 3 101
rs4843865 G 84,526,806 T/A 0.17/0.21 2.93 3 108 0.78 (0.72–0.85) 6.64 3 101 1.46 3 102
rs11347703 I 84,527,141 G/ 0.18/0.21 1.11 3 108 0.78 (0.72–0.85) 5.73 3 101 
rs8052690 G 84,527,239 A/G 0.18/0.21 5.69 3 108 0.79 (0.72–0.86) 6.58 3 101 5.28 3 103
rs186249 G 84,528,397 G/C 0.30/0.26 1.66 3 105 1.19 (1.10–1.28) 1.63 3 102 9.37 3 101
rs11117422 G 84,529,514 G/C 0.17/0.21 9.37 3 109 0.77 (0.71–0.84) 6.76 3 101 1.13 3 102
rs11644034 G 84,530,113 G/A 0.17/0.20 2.36 3 108 0.78 (0.71–0.85) 5.10 3 101 2.63 3 102
rs305066 I 84,530,277 C/T 0.33/0.29 8.18 3 106 1.18 (1.10–1.27)  3.62 3 101
rs13335265 G 84,530,311 C/G 0.16/0.20 1.23 3 108 0.77 (0.70–0.84) 2.86 3 101 1.06 3 102
rs12711490 G 84,530,529 A/G 0.17/0.20 2.11 3 108 0.78 (0.71–0.85) 4.51 3 101 7.55 3 102
rs11641153 I 84,530,641 A/G 0.16/0.20 1.31 3 109 0.76 (0.70–0.83) 4.85 3 101 7.02 3 102
rs11641155 I 84,530,653 A/G 0.16/0.20 1.23 3 109 0.76 (0.70–0.83)  7.02 3 102
rs7205434 I 84,530,696 C/G 0.16/0.20 1.23 3 109 0.76 (0.70–0.83) 4.85 3 101 7.02 3 102
rs4843868 I 84,530,902 C/T 0.16/0.20 8.57 3 1010 0.76 (0.70–0.83) 5.82 3 101 7.02 3 102
rs305063 G 84,532,158 C/A 0.32/0.29 7.34 3 105 1.17 (1.08–1.26)  9.66 3 101
rs4843323 I 84,532,462 C/T 0.16/0.20 7.71 3 1010 0.76 (0.70–0.83)  
rs4843869 I 84,532,642 G/A 0.16/0.20 7.61 3 1010 0.76 (0.70–0.83) 4.19 3 101 6.59 3 102
rs7202472 G 84,535,003 C/A 0.15/0.19 7.25 3 109 0.77 (0.70–0.84) 3.94 3 101 1.41 3 102
rs11117426 G 84,547,768 A/G 0.16/0.19 2.42 3 104 0.84 (0.77–0.92) 1.07 3 101 2.12 3 105
rs11117427 G 84,548,058 G/A 0.16/0.18 3.46 3 104 0.84 (0.77–0.93)  1.99 3 105
rs12445476 G 84,548,770 A/C 0.16/0.18 1.76 3 104 0.84 (0.76–0.92) 6.49 3 102 2.19 3 105
rs11642873 G 84,549,206 A/C 0.15/0.18 2.92 3 104 0.84 (0.77–0.92) 8.82 3 101 5.63 3 105
rs34912238 I 84,559,404 C/T 0.16/0.19 2.15 3 105 0.82 (0.75–0.90)  
The following abbreviations are used: G, genotyped; I, imputed; MAF, minor-allele frequency; OR, odds ratio; and CI, confidence interval.
aAll subjects, including the 374 that were removed so that the replication study was independent from the GWA scan, were imputed. Tables S4 and S5 contain
results for all populations evaluated within this study.
bMajor/minor alleles.
cCase/control.
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Figure 2. Conditional-Analysis Results Conducted in Individuals of European Ancestry
The results of the conditional analysis with the four SNPs show peak association in Europeans (rs8046526 and rs4843869), African Amer-
icans (rs450443), and Asians (rs11117427). The black dot represents the unadjusted single-marker association with SLE.haplotype and the minor alleles on the neutral H5 haplo-
type. Thus, it appears that all three regions (tagged by
rs8046526, rs450443, and rs4843869) are required for
risk. Many variants residing on the risk haplotype are
within regions known to bind multiple transcription
factors in the ENCODE ChIP-Seq project dataset in immu-
nologic cell types (Figures S3 and S4).49 Thus, we hypoth-
esize that the risk haplotype has the potential to affect
the regulation of IRF8 expression and/or the expression
of other genes in the region.
Within TMEM39A in region 3q13.33, a coding SNP
(rs1132200) that demonstrated suggestive evidence of
association in our previous GWA scan (p ¼ 1.65 3 103)
was also confirmed in the European replication study (p ¼
2.37 3 104, OR ¼ 0.83; Table 1 and Table S6). This nonsy-
nonymous SNP showed association with SLE in Asian
patients (p ¼ 1.66 3 103, OR ¼ 0.73) but not in African
Americans, Hispanics, Gullah, or Amerindians (Table 1
and Table S6). When analyzing this SNP in all populations
that passed quality control, a meta-analysis produced
pmeta-all ¼ 8.62 3 109, and no evidence of heterogeneity
was observed between these datasets (Table 1 and Table S6).
Finally, we replicated several SNPs in the 17q12 region
between IKZF3 and ZPBP2 (Table 1 and Table S6). Three
SNPs within IKZF3 replicated, and rs8079075 was the
most significant SNP in both the samples of European
(p ¼ 5.08 3 104, OR ¼ 1.39) and African American (p ¼
2.62 3 103, OR ¼ 1.26) ancestry (pmeta-all ¼ 4.83 3 109).
The most significant SNP in this region (rs1453560) is
located between IKZF3 and ZPBP2 and was replicated in
European (p ¼ 6.42 3 104, OR ¼ 1.37) and African
American (p ¼ 4.86 3 104, OR ¼ 1.23) ancestral popula-
tions; the replication resulted in pmeta-all ¼ 3.48 3 1010
(Table 1 and Table S6). All four SNPs are highly correlated
(r2 > 0.95). Even though Cochran’s Q test of heterogeneity
was not statistically significant, we observed moderate
heterogeneity by the I2 index, perhaps as a result of the
differences in allele frequency between the racial groupsThe Am(Table 1). IKZF3 and ZPBP2 are transcribed in opposite
directions of one another but share the same promoter
region (Figure S5). The ENCODE ChIP-Seq project has
identified multiple transcription-factor binding sites for
chromatin in the chromosomal region surrounding
rs1453560 (Figure S5).49
In addition to the three regions (described above) that
now exceed genome-wide significance, 11 loci were repli-
cated in the European SLE cases but did not exceed
genome-wide significance (5 3 108 < pmeta-Euro < 9.99 3
105). These 11 loci include the following: CFHR1 (MIM
134371), CADM2, LOC730109/IL12A (MIM 161560),
LPP (MIM 600700), LOC63920, SLU7 (MIM 605974),
ADAMTSL1 (MIM 609198), C10orf64, OR8D4, FAM19A2,
and STXBP6 (MIM 607958) (Table 3 and Table S7).Discussion
The interferon regulatory factors are a family of transcrip-
tion factors that play a critical role in the regulation of
several pathways, including the response to pathogens,
apoptosis, the cell cycle, and hematopoietic differentia-
tion.50 IRF8 is expressed in the nucleus (but partially
in the cytoplasm) of B cells, macrophages, and CD11b
dendritic cells (DCs).50 IRF8 can be induced by inter-
feron-g in macrophages and antigen stimulation within
T cells. It also plays an important role in the development
of B cells and macrophages.50 In the nucleus, IRF8 is
required for promoting type I interferon responses in
DCs upon viral stimulation.50 Interestingly, the overex-
pression of genes induced by type I interferons has been
widely reported in SLE and other autoimmune condi-
tions.12,51,52 In the cytosol, IRF8 is involved in the TLR9-
MyD88-dependent signaling by binding to TRAF6 in
both DCs and macrophages.50 After TLR9 stimulation,
DCs from mice that are Irf8/ cannot activate NF-kB or
MAPKs.50 Of note, rs17445836, which was not includederican Journal of Human Genetics 90, 648–660, April 6, 2012 655
Figure 3. IRF8 Haplotype and LD in the European Ancestral Population
(A) Haplotype structure in Europeans present at a frequency>3%.Major alleles are represented by red squares, whereas the green squares
are minor alleles.
(B and C) A LD plot of r2 (B) and D’ (C) in Europeans illustrates that the variants tagged by rs450443 and those tagged by rs4843869
are in weak r2 but strong D’, providing evidence that these variants are inherited together.in our study but has been associated withmultiple sclerosis
(MIM 126200), lies approximately 61 kb telomeric to IRF8
and is far removed from the regions identified in SLE.53
Finemapping, resequencing, imputation, and haplotype
analysis of the IRF8 locus in Europeans identified a single
haplotype requiring the presence of three independent
effects to confer risk. Additionally, several variants within
the IRF8 risk haplotype might influence binding to the
many regulatory elements present within the region.
Thus, we hypothesize that the likely functional effect
would result in altered IRF8 mRNA and protein expression.
Although we believe that most of the common variation
within the IRF8 region has been evaluated in this
study, it is possible that some variants with minor allele
frequencies <1% also play a role in SLE risk but were not
detected in our study because of the number of samples
resequenced.656 The American Journal of Human Genetics 90, 648–660, April 6, 2The TMEM39A-associated coding SNP (rs1132200)
results in an amino acid change from alanine to threonine
at position 487 of the protein. Although almost no
biological data have been published suggesting its rele-
vance to SLE, it has been found to be associated with
multiple sclerosis.54 Better understanding whether the
coding SNP in TMEM39A is functionally relevant or is
merely correlated with other unexamined causal polymor-
phism(s) will require mechanistic and fine-mapping
experiments.
Although the region surrounding the IKZF3-ZPBP2
locus at 17q21 has been associated with multiple pheno-
types, the extensive LD in the region has prohibited inves-
tigators from clearly determining the relevant gene. Crohn
disease (MIM 266600), ulcerative colitis (MIM 266600),
primary biliary cirrhosis (MIM 109720), and rheumatoid
arthritis (MIM 180300) all have reported associations012
Table 3. Replicated Loci that Demonstrate Suggestive Evidence of SLE Riska
SNP Locus Allelesb
European
Test of
Heterogeneity
pGWA scan
c
ORGWA scan
(95% Cl) pREP ORREP (95% Cl) pMETA-Euro pQ
d I2
rs7542235 CFHR1 A/G 3.94 3 103 1.30 (1.11–1.54) 1.10 3 103 1.15 (1.06–1.25) 1.85 3 105 0.180 44.4%
rs485499 LOC730109/
IL12A
A/G 2.14 3 103 0.75 (0.65–0.87) 1.47 3 104 0.87 (0.81–0.94) 1.31 3 106 0.076 68.2%
rs669003 LOC730109/
IL12A
A/G 2.16 3 103 0.75 (0.65–0.87) 1.15 3 104 0.87 (0.81–0.93) 1.02 3 106 0.081 67.2%
rs7631930 LPP A/G 3.60 3 103 1.25 (1.06–1.49) 1.66 3 103 1.15 (1.05–1.25) 2.71 3 105 0.375 0.00%
rs9310002 CADM2 G/A 2.09 3 103 2.06 (1.38–3.07) 6.12 3 103 1.39 (1.10–1.76) 8.30 3 105 0.099 63.3%
rs1075059 LOC63920 A/C 7.30 3 104 0.82 (0.71–0.95) 7.26 3 103 0.91 (0.85–0.97) 5.27 3 105 0.221 33.2%
rs1895321 SLU7 A/C 4.21 3 103 1.22 (1.06–1.41) 3.11 3 103 1.11 (1.04–1.19) 6.09 3 105 0.260 21.2%
rs7039790 ADAMTSL1 C/A 5.36 3 103 1.62 (1.24–2.12) 1.14 3 103 1.27 (1.10–1.47) 2.38 3 105 0.124 57.7%
rs2940712 C10orf64 G/A 4.72 3 103 0.79 (0.67–0.91) 8.73 3 104 0.88 (0.82–0.95) 1.62 3 105 0.178 45.0%
rs10790605 OR8D4 G/A 2.02 3 103 0.80 (0.67–0.95) 4.35 3 103 0.88 (0.81–0.96) 5.39 3 105 0.321 0.00%
rs7960162 FAM19A2 A/G 4.95 3 103 0.76 (0.61–0.94) 4.31 3 103 0.87 (0.79–0.96) 9.79 3 105 0.253 23.6%
rs749373 STXBP6 A/G 5.44 3 103 1.34 (1.11–1.62) 2.32 3 103 1.16 (1.05–1.27) 5.26 3 105 0.171 46.7%
The following abbreviation is used: GWA, genome-wide association; OR, odds ratio; CI, confidence interval; and REP, replication.
aTable S7 contains results for all populations evaluated within this study.
bMajor/minor alleles.
cGWA scan previously reported in Graham et al.1
dCochran’s Q test statistic.with genes between 34.62–35.51 Mb of chromosome
17.55–60 Fine mapping and resequencing of this region in
Europeans and African Americans are needed if researchers
are to more precisely refine this association and determine
the loci associated with risk. IKZF3 is a member of the
IKAROS family of transcription factors involved in
lymphocyte development; IKZF1 in this family has already
been reported as a risk locus for SLE.22 Mice with a mutant
form of IKZF3 produce anti-dsDNA autoantibodies,
making it an interesting candidate gene for human
SLE.61 Moreover, mice that are null for IKZF3 and OBF-1
(POU class 2 associating factor 1) do not mount an autoim-
mune response.61 The peak signal in our study was in
a region containing multiple regulatory elements, so it is
likely that the associated SNP could affect expression of
IKZF3 or ZPBP2, which both share the promoter region.
However, no known function of ZPBP2 has been reported.
Eleven additional regions were replicated in the Euro-
pean subjects but did not surpass genome-wide signifi-
cance. Of these regions, LOC730108/IL12A was previously
reported as a risk locus for primary biliary cirrhosis and
multiple sclerosis.60,62 IL-12A induces interferon-gamma
and helps differentiate Th1 and Th2 cells.63 The response
of lymphocytes to IL-12A is mediated by STAT4, which is
also implicated in SLE pathogenesis.64 The LIM domain
containing preferred translocation partner in lipoma
(LPP) is involved in focal adhesions, cell-cell adhesion,
and cell motility. Variants within the LPP region have
been associated with vitiligo and celiac disease.65,66 Con-The Amfirmation of these associations will require replication in
a larger independent and equally diverse population.
In conclusion, we have robustly established three
additional susceptibility loci for SLE: IRF8, TMEM39A,
and IKZF3-ZPBP2. Eleven other regions were replicated
but did not exceed the genome-wide threshold of signifi-
cance. Collectively, these data, along with other previously
reported loci, demonstrate the growing complexity of
the heritable contribution to SLE pathogenesis. A complete
understanding of how genetics influence the pathophysi-
ology of SLE will only be possible once we have identified
all contributing loci and functional and/or causal variants
for each association and have extensively evaluated the
role of rare variants. More work will be required if we are
to increase our understanding of how the loci identified
in this study influence SLE etiology.Supplemental Data
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